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Multiple sclerosis (MS) is a chronic, inflammatory and neurodegenerative disorder of the central nervous system (CNS) that evolves over time clinically by a variable course 1 , characterized by the appearance of multiple areas of myelin destruction, axonal loss and reactive gliosis 2 . Research during the last decade demonstrated not only focal but also diffuse damage affecting white, as well as grey, matter and neurodegeneration occurring in early stages of the disease [2] [3] [4] [5] [6] . This damage and consequent tissue loss lead to spinal and brain atrophy, reflecting the underlying and permanent neuroaxonal destruction produced 2, 5 . Most patients develop significant disability 15-30 years after the onset of the disease as an expression of the aforementioned 1, 7 . However, long term prognosis is difficult to predict at the beginning, since clinical and paraclinical parameters currently used in the clinical setting are not reliable prognostic factors 8, 9 . Few recent studies suggest that early brain atrophy changes would predict long term disability 3, 5, 6, 10, 11 . These studies have been carried out in MS and in clinically isolated syndrome (CIS) patients, reporting valuable, but inconclusive data, determining whether brain atrophy in early stages is a valuable predictor of disease progression 3, 5, 10, 12 . A sensible and specific disease progression biomarker at the beginning of the disease might optimize treatment decisions 11 . The aim of the present study was to investigate in a South American cohort of relapsing-remitting MS (RRMS) patients whether brain atrophy changes during the first year following disease onset independently predicted long term physical disability.
METHODS

Patients
This study was designed as a cohort study. Patients were identified from a longitudinal cohort of MS patients from the MS Center of the Hospital Italiano de Buenos Aires, Argentina. Patients with MS (Poser or McDonald criteria 13, 14 ), with a follow-up time of at least seven years from disease onset (defined as a single event of acute onset in the CNS suggestive of demyelination: for example, unilateral optic neuritis, brainstem and partial spinal cord syndromes 8 ). Patients must also have a baseline and second magnetic resonance (MR) 12 months later.
Clinical and paraclinical data analyzed Age, gender, clinical onset, Expanded Disability Status Scale (EDSS) at onset and during follow-up (every three months) and number of relapses were recorded. All patients were followed for at least seven years. Paraclinical data obtained at onset were: serological tests for differential diagnosis, including antinuclear antibodies, B12 vitamin and folate levels, VDRL and HIV tests, and oligoclonal bands (OB) detection in cerebrospinal fluid (CSF) and serum samples performed by agarose isoelectric focusing combined with immunoblotting and avidin-biotin amplified double-antibody peroxidase staining. Brain MR was performed on a 1.5 Tesla machine with a standard head coil (Siemens Avanto) within two months of the first demyelinating event. MR study included images obtained in the following sequences: T1-weighted conventional spin-echo; T2-weighted fast spin-echo; FLAIR spin-echo and T1-weighted conventional spin-echo after single doses of gadolinium (0.1 mg/kg). All images had a section thickness of 3 mm and an intersection gap of 0.5 mm. A second MR was performed between 11 and 14 months after the first one, with the same machine, with the same acquisition sequences and patient alignment.
Brain atrophy measurement
Images were processed and analyzed in the neurological lab of the Hospital Italiano MS Center by a blinded physician. For brain atrophy analysis, percentage of brain volume change (PBVC) between baseline and one year was estimated from T1 weighted images with SIENA software (Structural Image Evaluation using Normalization of Atrophy), a part of the FSL library 15 . SIENA extracts brain and skull images from twotimepoint whole-head input data. The two images are then aligned to each other. Both brain images are resampled into the space halfway between the two. Next, tissue segmentation is carried out in order to find brain/no brain edge points, and then perpendicular edge displacement (between the two time points) is estimated at these edge points. Finally, the mean edge displacement is converted into a global estimate of PBVC between the two timepoints 15 .
In addition to brain atrophy rate, T2 weighted lesion volumes at baseline were calculated. Follow-up brain scans were also used to determine T2 weighted lesion volume at one year and thus calculate the one year change on T2 lesion volume. The software used to segment and calculate T2 lesion load was SepINRIA by lesion segmentation edition 16 .
Statistical analysis
Data were stored and analyzed in STATA 9.1 software. All PBVC were annualized prior to statistical analysis. Ordinal logistic regression was used to determine which clinical and paraclinical variable, including MR, were related to disability assessed by EDSS during follow-up. EDSS was categorized in three groups, EDSS=0, EDSS between 1 and 2.5, and EDSS≥3. These groups were chosen because they were previously considered to represent different levels of disability 5 . Clinical and paraclinical variables were evaluated for independent prediction of progression in a logistic regression model. Regarding MR variables, PBVC, baseline T2 lesion volume and T2 lesion volume changes between baseline and one year after onset MR were considered as potential predictors in the analysis, p<0.05 was considered statistically significant.
RESULTS
Twenty-six patients fulfilled criteria and consequently were included in the study. Fifteen patients were female, and mean age at onset was 32.8±9 years. Mean follow-up time of the cohort was 9.3±2.5 years. Patient's demographic, clinical and paraclinical data are displayed in Table 1 . All patients were under immunomodulatory treatments. PBVC between baseline and year 1 MR was -0.57±0.63%/year. Mean T2 lesion volume at baseline was 1.756±3.650 mm 3 , and mean increase in T2 lesion volume at 1 year was 756±2.768 mm 3 for the whole cohort. Eleven (42.3%) patients reached an EDSS≥3, 12 (46.2%) had an EDSS between 1 and 2.5, and 3 (11.5%) had an EDSS of 0 when analysis were undertaken. Mean PBVC during the first year in patients that reached and EDSS≥3 was -0.76±0.45 %/year, in patients that had an EDSS between 1 and 2.5 were -0.59±0.56, while in patients with an EDSS of 0 the PBVC during the first year was -0.38±0.42 (p=0.003) (Figure) . PBVC at year 1 was the only variable associated with physical disability measured by EDSS. Other clinical and radiological variables did not show association with disability (Table 2, Figure) .
DISCUSSION
This study showed that brain atrophy changes during the first year after disease onset estimated by PBVC were associated with a worse outcome in terms of disability. It should be noted that the prediction of disability in patients with higher brain atrophy during the first year of disease onset was independent from other clinical and MR parameters, such as the presence of OB in CSF, EDSS at onset, T2 lesion load at baseline and increase of T2 lesion load at first year from disease onset (Table 2) .
Currently, no studies have investigated the predictive value of lesion load and brain atrophy measures for disability at the beginning of MS with long clinical follow-up and none have been focused on MS patients in South America. One study, performed by Di Filippo et al. 5 in CIS patients with a prospective view considers clinical and MR aspects at the beginning of the disease to predict disability measured by EDSS, as well as by multiple sclerosis functional composite (MSFC). The study, that included nearly 100 patients, showed that in the univariate analysis the PBVC during the first year of disease onset was associated with disability, but, when logistic regression and multivariable adjustment were applied, increase in T2 lesion load over the first year and baseline Gd enhancing lesion number were found to be the only independent predictors of disability measured by the EDSS after six years. We found higher PBVC than Di Filippo et al. (-0.57±0.63 %/year versus -0.38±0.55 %/year), that might be explained by differences in the inclusion criteria: only half of their CIS cohort converted to MS while all of our patients had MS.
Another study 3 performed in patients with RRMS reported that brain atrophy rate measured by PBVC over two years was a predictor of disability after eight years.
Unlike Di Filippo et al. 5 , we found no association between the increase of T2 lesion load during the first year and the increase of disability; however, a tendency did exist, though there was no association (p=0.07) due to the low number of patients included in our cohort.
Several limitations of this study must be noted. The design of the study, a retrospective cohort, means that some records might be missing. Notwithstanding, in the MS Center of the Hospital Italiano, patients are strictly followed every three months and records are standardized so that every patient included in this study, as well as those not included in the study, have their records fully registered. At the same time, physicians who follow patients have vast experience in the disease, with certified qualifications to perform the EDSS scale carried out on each patient visit (every three months). Another bias to consider is the impact that disease modifying drugs could have in disability progression during the follow-up 3 . However, as all patients converted to MS and, consequently, all patients received disease modifying drugs (DMD) during the followup, this bias could be partially controlled. A final limitation 
